Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to.

TitleFluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to.
Publication TypeJournal Article
Year of Publication2018
AuthorsHenriques ADallanora, Benedet ALessa, Camargos EFrancisco, Rosa-Neto P, Nóbrega OToledo
JournalExp Gerontol
Date Published2018 Jan 04
ISSN1873-6815
Abstract

There is increasing evidence that a number of potentially informative biomarkers for Alzheimer disease (AD) can improve the accuracy of diagnosing this form of dementia, especially when used as a panel of diagnostic assays and interpreted in the context of neuroimaging and clinical data. Moreover, by combining the power of CSF biomarkers with neuroimaging techniques to visualize Aβ deposits (or neurodegenerative lesions), it might be possible to better identify individuals at greatest risk for developing MCI and converting to AD. The objective of this article was to review recent progress in selected imaging and chemical biomarkers for prediction, early diagnosis and progression of AD. We present our view point of a scenario that places CSF and imaging markers on the verge of general utility based on accuracy levels that already match (or even surpass) current clinical precision.

DOI10.1016/j.exger.2018.01.002
Alternate JournalExp. Gerontol.
PubMed ID29307736
Grant ListP41 EB015904 / EB / NIBIB NIH HHS / United States

  • Douglas Hospital
  • Dobell Pavillion
  • Brain imaging centre